Clinical Trials Directory

Trials / Sponsors / Allogene Therapeutics

Allogene Therapeutics

Industry · 9 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in A
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Phase 12025-11-13
Enrolling By InvitationFollow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Hematologic Malignancies, Solid Tumors
—2025-01-31
RecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Phase 22024-06-18
TerminatedEvaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allog
Relapsed/Refractory Large B Cell Lymphoma
Phase 22023-11-01
TerminatedSafety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractor
Relapsed/Refractory Multiple Myeloma
Phase 1 / Phase 22021-06-06
Active Not RecruitingSafety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Phase 12021-02-24
Active Not RecruitingSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B C
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Phase 1 / Phase 22020-05-21
Active Not RecruitingSafety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple M
Relapsed/Refractory Multiple Myeloma
Phase 12019-09-23
CompletedSafety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Ce
Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
Phase 12019-05-01